Oncology Business Management | Specialty

Control Arms Must Be Selected for Meaningful Comparison

July 24th 2019

Although concerns have been raised in recent years regarding the need for randomized trials to augment the body of clinical understanding, one critical issue that has failed to generate sufficient discussion is how the choice of the control arm affects the interpretation of an individual study’s outcome and potentially undermines the ethical basis for that particular study.

Statistics Show Increase in US Cancer Survivors

July 20th 2019

The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.

Report Highlights Struggle to Help Survivors Prepare for Life After Treatment

July 19th 2019

A strong unmet need for survivorship care plans exists in the cancer treatment community and better follow-up is required for patients who have moved on from treatment and are experiencing its aftereffects.

CMS Unveils Proposed Radiation Oncology Model of Care

July 18th 2019

Until now, radiation oncology (RO) has remained largely untouched by the valuebased initiatives of the Centers for Medicare and Medicaid Services. The federal agency aims to change that with a proposed RO Model of care that would promote site-neutral payment and take away incentives for volume-based billing.

Dr. Norden on Differences Between mCODE and Cota's CNA Network

July 16th 2019

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.

Open-Access Publishing Model May Introduce New Biases in Oncology

July 15th 2019

For clinical science, particularly oncology, there has never been a more exciting era than today.

Oncology Practices Can Preserve Independence With a Strong Marketing Effort

June 29th 2019

From 2016 to 2018, there was an 8% increase in the number of community oncology practices consolidated into hospital systems, and this trend has many independent practices struggling to avoid the same fate. Two winning strategies are emerging to help practices remain independent.

Evolutionary Medicine May Provide Clues for Cancer Genetics

June 28th 2019

Today, with the routine performance of single gene or germline panel testing, as well as a critical focus on prospective follow-up of individuals with incompletely understood germline variants, clinicians are developing an increasingly robust appreciation for the influence of an individual’s genetic background on the likelihood of developing specific malignancies or a group of malignant conditions.

Experts Highlight Ongoing Research Efforts Across Tumor Types

June 28th 2019

OncLive interviewed experts at the State of the Science Summits in June 2019 on research being conducted at their respective institutions.

Clinics Strive to Improve Revenue and Patient Care Amid a Growing "Cost Consciousness"

June 26th 2019

Growing awareness is prompting a revolution in vigilance and attention to detail that has significance both for the quality of care and financial health of practices.

Pfizer Acquires Array BioPharma in $11.4 Billion Deal

June 18th 2019

Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.

Vaccine Opponents Haven't Looked at the Evidence

June 11th 2019

It may be difficult for many who have not lived through an outbreak to appreciate how critical it is to never permit the disease to reappear.

Oncology Community Remembers Legendary Researcher Henry T. Lynch

June 6th 2019

Henry T. Lynch, MD, the Charles F. and Mary C. Heider Endowed Chair in Cancer Research at Creighton University and a 2019 Giants of Cancer Care® award winner known by many as the “father of cancer genetics,” died June 2 at the age of 91.

Evolutions in the Treatment of EGFR-Mutated NSCLC

June 4th 2019

Sequencing With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Second- and Third-Generation TKIs in EGFR-Mutated NSCLC

June 4th 2019

Treating With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Resistance to Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

June 4th 2019

ASCO 2019: Oncology Leaders Select Top Studies

May 29th 2019

Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.